Date | Open(₹) | High(₹) | Low(₹) | Close(₹) | No. Of Trades(₹) | Total Turnover(₹) | Deliverable Quantity(₹) |
|---|---|---|---|---|---|---|---|
14-Oct-2026 | 973 | 984.7 | 953.6 | 962.1 | 37,670 | 51,65,98,644.2 | 2,58,517 |
15-Oct-2026 | 967.9 | 969.5 | 917.5 | 922.1 | 55,258 | 77,75,77,780.3 | 4,72,978 |
16-Oct-2026 | 920 | 962 | 913 | 937.6 | 48,528 | 68,02,46,122.4 | 3,05,597 |
19-Oct-2026 | 890 | 919.9 | 855.2 | 876.2 | 1,04,112 | 2,06,98,46,303.9 | 11,25,137 |
21-Oct-2026 | 855.1 | 882.9 | 835.8 | 845.2 | 71,383 | 1,21,30,75,953.5 | 6,64,533 |
22-Oct-2026 | 826.3 | 894.2 | 820.4 | 860.8 | 64,395 | 1,29,66,07,613.5 | 4,41,420 |
23-Oct-2026 | 860.8 | 883 | 838.8 | 864.3 | 49,312 | 82,40,62,867.6 | 3,99,910 |
26-Oct-2026 | 880 | 908.9 | 860 | 900.8 | 54,136 | 77,24,94,942.3 | 3,33,344 |
27-Oct-2026 | 912.6 | 924 | 895.1 | 904.7 | 26,284 | 37,24,63,762.5 | 1,48,654 |
28-Oct-2026 | 909 | 937.3 | 906 | 932 | 30,134 | 53,02,38,103.9 | 2,99,702 |
29-Oct-2026 | 932 | 949.8 | 922.9 | 935.6 | 26,524 | 36,16,28,943.6 | 1,69,686 |
30-Oct-2026 | 955.9 | 979.8 | 930.3 | 955.6 | 55,238 | 86,06,66,597.3 | 3,60,139 |
02-Nov-2026 | 957 | 961 | 916.25 | 924.55 | 30,958 | 51,87,64,131.35 | 2,62,533 |
03-Nov-2026 | 931 | 954.35 | 923 | 932.05 | 32,724 | 36,77,68,526.75 | 1,86,376 |
04-Nov-2026 | 926.1 | 936.05 | 893.05 | 931.1 | 42,745 | 50,07,30,201.8 | 2,62,624 |
05-Nov-2026 | 950.55 | 960 | 874.3 | 921.8 | 1,07,553 | 2,08,01,90,116.85 | 5,98,644 |
06-Nov-2026 | 901.85 | 969.8 | 901.85 | 942.35 | 60,734 | 1,13,40,60,061.65 | 4,92,506 |
08-Nov-2026 | 964 | 968 | 927 | 953.65 | 10,326 | 25,29,82,842.2 | 1,43,454 |
09-Nov-2026 | 953.65 | 977 | 931 | 933.85 | 26,413 | 51,51,28,177 | 2,52,057 |
11-Nov-2026 | 940 | 964.1 | 924 | 934.15 | 35,128 | 62,66,36,638.45 | 3,20,145 |
12-Nov-2026 | 939.5 | 1,005 | 939.5 | 989.65 | 36,689 | 89,11,28,195.7 | 4,54,250 |
It targets to initiate first-in-human clinical trials in patients with Essential Thrombocythemia and Polycythemia Vera.
Here are some of the stocks that may see significant price movement today: Larsen & Toubro, Lodha Developers, Shilpa Medicare, etc.
USFDA conducted the Good Manufacturing Practices (GMP) inspection from October 24 to October 30 in 2024.
The certification came after a successful inspection by the Finnish Medicines Agency on behalf of EMA from March 10 to March 14, 2025
The partnership will work on a new biological entity (NBE) in the immuno-oncology field to better treat cancer.
Here are some of the stocks that may see significant price movement today: Aditya Birla Real Estate, Shilpa Medicare, Swiggy, etc.
No regulatory issues were raised by the USFDA at Unit-2 during the inspection, the company said in a regulatory filing.
Shilpa Medicare said it has completed Phase 3 trials for SMLNUD07 – Nor Ursodeoxycholic Acid (Nor UDCA) tablets in 165 NAFLD patients in India.
The certification followed a successful inspection by the European Medicines Agency, Austria, held from September 24 to September 26 at the Nacharam, Hyderabad facility.
This FDA approval is a milestone in cancer therapy as it presents a more convenient and precise alternative to the traditional tablet forms.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
